Topoisomerase II inhibitors affect entry into mitosis and chromosome condensation in BHK cells

Cell Growth and Differentiation

Volumn 7, Issue 1, 1996, Pages 83-90

  Anderson, Hilary ^a   Roberge, Michel ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACLARUBICIN; DEMECOLCINE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; FOSTRIECIN; GYRASE INHIBITOR; MERBARONE; NSC 94528; OKADAIC ACID; RAZOXANE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CYCLE G2 PHASE; CELL STRAIN BHK; CHROMATIN CONDENSATION; CONTROLLED STUDY; DNA STRAND BREAKAGE; ENZYME INHIBITION; MITOSIS; NONHUMAN; PRIORITY JOURNAL;

ACLARUBICIN; ALKENES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CELL LINE; CHROMOSOMES; CRICETINAE; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; ENZYME INHIBITORS; ETOPOSIDE; G2 PHASE; GUANINE NUCLEOTIDE EXCHANGE FACTORS; KIDNEY; MITOSIS; NUCLEAR PROTEINS; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE; PYRONES; RAZOXANE; TEMPERATURE; THIOBARBITURATES;

ANIMALIA; MAMMALIA; STAPHYLOCOCCUS PHAGE 187;

EID: 0030023438     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Anderson, H. J., and Roberge, M. DNA topoisomerase II: a review of its involvement in chromosome structure, DNA replication, transcription and mitosis. Cell Biol. Int. Rep., 16: 717-724, 1992.
2. Roca, J. The mechanisms of DNA topoisomerases. Trends Biochem Sci., 20: 156-160, 1995.
3. Gasser, S. M., Laroche, T., Falquet, J., Boy de la Tour, J., and Laemmli, U. K. Metapnase chromosome structure: involvement of topoisomerase II. J. Mol. Biol., 188: 613-629, 1986.
4. Uemura, T., and Yanagida, M. Isolation of type I and II DNA topoisomerase mutants from fission yeast: single and double mutants show different phenotypes in cell growth and chromatin organization. EMBO J., 3: 1737-1744, 1984.
5. DiNardo, S., Voelkel, K., and Sternglanz, R. DNA topoisomerase II mutants of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. Proc. Natl. Acad. Sci. USA, 81: 2616-2620, 1984.
6. Holm, C., Goto, T., Wang, J. C , and Botstein, D. DNA topoisomerase II is required at the time of mitosis in yeast. Cell, 41: 553-563, 1985.
7. Uemura, T., Ohkura, H., Adachi, Y., Morino, K., Shiozaki, K., and Yanagida, M. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe. Cell, 50: 917-925, 1987.
8. Holm, C. Coming undone: how to untangle a chromosome. Cell, 77: 955-957, 1994.
9. Wood, E. R., and Earnshaw, W. C. Mitotic chromatin condensation in vitro using somatic cell extracts and nuclei with variable levels of endogenous topoisomerase II. J. Cell Biol., 111: 2839-2850, 1990.
10. Adachi, Y., Luke, M., and Laemmli, U. K. Chromosome assembly in vitro: topoisomerase II is required for condensation. Cell, 64: 137-148, 1991.
11. Hirano, T., and Mitchison, T. J. Topoisomerase II does not play a scaffolding role in the organization of mitotic chromosomes assembled in Xenopus egg extracts. J. Cell Biol., 120: 601-612, 1993.
12. Vassetzky, Y. S., Dang, Q., Benedetti, P., and Gasser, S. M. Topoisomerase II forms multimers in vitro: effects of metals, β-glycerophosphate, and phosphorylation of its COOH-terminal domain. Mol. Cell. Biol., 14: 6962-6974, 1994.
13. Liu, L. F DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58: 351-375, 1989.
14. Zhang, H., D'Arpa, P., and Liu, L. F. A model for tumor cell killing by topoisomerase poisons. Cancer Cells, 2: 23-27, 1990.
15. 2 and mitotic BHK cells. J. Cell Biol., 111: 1753-1762, 1990.
16. Charron, M., and Hancock, R. DNA topoisomerase II is required for formation of mitotic chromosomes in Chinese hamster ovary cells: studies using the inhibitor 4′-demethylepipodophyllotoxin 9-(4,6-O-thenylidene-β-D-glucopyranoside). Biochemistry, 29: 9531-9537, 1990.
17. 2 arrest in Chinese hamster ovary cells. Cancer Res., 50: 3761-3766, 1990.
18. cdc2 tyrosine dephosphorylation, and mitotic progression in Chinese hamster ovary cells exposed to etoposide Cancer Res., 52: 1817-1822, 1992.
19. Li, J. J., and Deshaies, R. J. Exercising self-restraint: discouraging illicit acts of S and M in eukaryotes Cell, 74: 223-226, 1993.
20. Murray, A., and Hunt, T. The Cell Cycle: an Introduction, pp., 139-144. New York: W. H. Freeman and Company, 1993.
21. Hartwell, L , Weinert, T , Kadyk, L , and Garvik, B. Cell cycle check-points, genomic integrity, and cancer. Cold Spring Harbor Symp. Quant. Biol., 59: 259-263, 1994.
22. Drake, F. H., Hofmann, G. A., Mong, S-M., O'Leary Bartus, J., Hertzberg, R. P., Johnson, R. K., Mattern, M. R., and Mirabelli, C. K. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res , 49: 2578-2583, 1989.
23. Chen, M., and Beck, W. T. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase IIα when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res., 53: 5946-5953, 1993.
24. Jensen, P. B., Sorensen, B. S., Demant, E. J. F., Sehested, M , Jensen, P. S., Vindelov, L., and Hansen, H. H. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-9-acridinylamino)methanesulfon-manisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res., 50: 3311-3316, 1990.
25. Sehested, M., Jensen, P. B., Sorensen, B. S., Holm, B., Friche, E., and Demant, E. J. F. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem. Pharmacol., 46: 389-393, 1993.
26. 2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26. Cancer Res., 55: 1509-1516, 1995.
27. Sharpe, H. B. A., Field, E. O., and Hellmann, K. Mode of action of the cytostatic agent "ICRF 159." Nature (Lond.), 226: 524-526, 1970
28. Ishida, R., Miki, T., Nanta, T., Yui, R., Sato, M., Utsumi, K. R., Tanabe, K., and Andoh, T. Inhibition of intracellular topoisomerase II by antitumour bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of the cleavable complex-forming type inhibitors. Cancer Res., 51: 4909-4916, 1991.
29. 2 checkpoint in mammalian cells. Nature (Lond.), 372: 467-470, 1994
30. Ishida, R., Sato, M., Nanta, T., Utsumi, K. R., Nishimoto, T., Morita, T., Nagata, H., and Andoh, T. Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events. J. Cell Biol., 126: 1341-1351, 1994.
31. Gorbsky, G J. Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane: ADR-529] and ICRF-159 (Razoxane). Cancer Res., 54: 1042-1048, 1994
32. Nishimoto, T. The "BN2," a regulator for the onset of chromosome condensation. BioEssays, 9: 121-124, 1988.
33. Roberge, M. Checkpoint controls that couple mitosis to completion of DNA replication. Trends Cell Biol., 2: 277-281, 1992.
34. Roberge, M., Tudan, C. T , Hung, S. M. F., Harder, K. W., Jirik, F. R., and Anderson, H. J. Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A. Cancer Res., 54: 6115-6121, 1994.
35. Drake, F. H., Hofmann, G A., Bartus, H. F., Mattern, M. R., Crooke, S T., and Mirabelli, C K. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry, 28: 8154-8160, 1989
36. Roca, J., Ishida, R., Berger, J. M., Andoh, T., and Wang J C Antitumor bisdioxopiperazmes inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed clamp. Proc. Natl. Acad. Sci USA, 91. 1781-1785, 1994.
37. Sorensen, B. S., Sinding, J., Andersen, A. H., Alsner, J., Jensen, P. B., and Westergaard, O. Mode of action of topoisomerase II-targeting agents at a specific DNA sequence: uncoupling the DNA binding, cleavage and religation events. J. Mol. Biol., 228: 778-786, 1992.
38. Sorensen, B. S., Jensen, B. P., Sehested, M., Jensen, P S., Kjeldsen, E., Nielsen, O. F., and Alsner, J. Antagonistic effect of aclarubicin on camptothecin induced cytotoxicity: role of topoisomerase I Biochem. Pharmacol., 47: 2105-2110, 1994.
39. 2 arrest in Chinese hamster ovary cells treated with anticancer drugs. J. Natl. Cancer Inst., 57: 1139-1143, 1976.
40. Sandell, L. L., and Zakian, V. A. Loss of a yeast telomere: arrest, recovery, and chromosome loss Cell, 75: 729-739, 1993.
41. van Holde, K. E. Chromatin, pp. 289-354. New York: Springer-Verlag, 1989.
42. Alberts, B., Bray, D., Lewis, J., Raff, M., Roberts, K., and Watson J. D. Molecular Biology of the Cell, pp. 346-356. New York: Garland Puolishing, Inc , 1994.
43. Boy de la Tour, E., and Laemmli, U. K. The metaphase scaffold is helically folded: sister chromatids have predominantly opposite helical handedness. Cell, 55: 937-944, 1988.
44. 2 arrested cells are easily analyzed by use of the "tsBN2" mutation. Cell Struct. Funct., 10: 417-420, 1985
45. cdc2 kinase activity and histone H1 hyperphosphorylation but is associated with enhanced histone H2A and H3 phosphorylation. EMBO J., 14: 976-985, 1995.